SPORE-BASED PROBIOTIC COMPOSITION FOR MODULATION OF MICROBIOME IN HUMANS
A spore-based probiotic composition is provided that comprises at least one viable probiotic microorganism having a biological or therapeutic effect on microbiome in humans. One exemplary composition contains five different strains of Bacillus spp. Also provided are methods of producing spore-based probiotic compositions. A validated in vitro gut model which is a simulated human intestinal microbial ecosystem reactor was used to assess the long-term effect of the composition on microbial metabolic activity and community composition. The results support use of the composition in protecting against obesity-related disorders, metabolic disorders, inflammation, and cancer, for example. A method for modulating microbial metabolic activity and/or modulating microbial community composition in a human subject is described.
1 . A method for modulating microbial metabolic activity or microbial community composition in a human subject, comprising administering to the human subject an effective amount of a spore-based probiotic composition comprising strains Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans SC-208, Bacillus clausii SC-109, and Bacillus licheniformis SL-307, each strain comprising Bacillus spores, wherein a health outcome is improved in the human subject.
2 . The method of claim 1 , wherein the health outcome is protection against a condition selected from the group consisting of obesity-related disorders, metabolic disorders, inflammation, and cancer.
3 . The method of claim 1 , wherein one or more of acetate, propionate, or butyrate is increased in the human gastro-intestinal tract
4 . The method of claim 1 , wherein the spore-based probiotic composition is administered in a daily dose of about 4×10 9 Bacillus spores (CFUs).
5 . A method for increasing microbial diversity in the gastro-intestinal tract in a human subject, comprising administering to the human subject an effective amount of a spore-based probiotic composition comprising strains Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans SC-208, Bacillus clausii SC-109, and Bacillus licheniformis SL-307, each strain comprising Bacillus spores.
6 . The method of claim 5 , wherein Bifidobacteriaceae family colonization is increased in the human gastro-intestinal tract.
7 . The method of claim 5 , wherein Faecalibacterium prausnitzii colonization is increased in the human gastro-intestinal tract.
8 . The method of claim 5 , wherein Akkermansia muciniphila colonization is increased in the human gastro-intestinal tract.
9 . The method of claim 5 , wherein the Firmicutes:Bacteroidetes phyla ratio is increased by about 50% or greater in the human gastro-intestinal tract.
10 . The method of claim 5 , wherein the spore-based probiotic composition is administered in a daily dose of about 4×10 9 Bacillus spores (CFUs).